Jason Broderick | Authors


Atezolizumab Combined With Cabozantinib Shows Efficacy in High-Risk mCRPC

September 19, 2021

According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.

Adding 177Lu-PSMA-617 to Standard of Care Significantly Prolongs Survival in mCRPC

July 20, 2021

In patients with progressive prostate-specific membrane antigen positive metastatic castration-resistant prostate cancer receiving treatment in the phase 3 VISION trial, the addition of the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death versus SOC alone.